When I grow up, I want to bottom-tick a turnaround. It's been an expensive hobby, but could this be the one?

Peak used to be Althea Group. They are now a focused producer of THC-infused drinks, with white label and own brands. They dominate the Canada market, and are positioned with major deals for the USA, ready to move into states markets that open up.

There is regulatory uncertainty in the USA, however, the medium term trend is favourable.There's a story there about the hemp-derived THC market which I might try to write a straw on later. Long story short, it favours larger producers who can pivot. Peak is the enabler to larger producers, who want to plug and play THC into their wider beverage stable.

Infusion is not easy. It requires experience to deliver reliable and palate-friendly product at scale. They have this, which is evidenced by their deals.

It would take a proper analyst to say how strong the finances are from here, but I feel like they have largely cleaned up a mess and revealed an interesting proposition.

Canada production:

Investment Highlights:

~ Althea has completed its first shipment of medicinal cannabis products to Germany

~ Initial shipment of 2,000 units valued at approximately $1,000,000 (EUR640,000)

~Althea has partnered with one of the country’s leading pharmaceutical wholesalers of cannabis-based medicines, Nimbus Health GmbH, to launch the brand exclusively in Germany

~ Under Althea and Nimbus’ agreement, Althea will receive payment for products supplied to Nimbus, along with 50% of net profit

~The German medicinal cannabis market is the largest medicinal cannabis market in Europe and health insurers typically cover the entire cost of medicinal cannabis treatments

December sales exceed $1.19M with 90% monthly growth in UK

Investment Highlights:

• Althea achieved record sales of $1,190,473 in December 2020, an increase of 40% from November 2020, and the first time monthly sales have exceeded $1 million

• Australian sales were a record $902,466 for December 2020, an increase of 22% month-on month

• UK sales were a record $209,706 in December 2020, an increase of 90% from November 2020, and further evidence of Althea’s first-mover advantage in the territory

07-May-2020:  Phillip Capital: Althea Group (AGH): Ground floor opportunity in Germany; Canada launch imminent

PC have upgraded AGH from "Hold"  to "Accumulate" and they have upgraded their TP from 29 cps to now 57 cps.  High Risk Rating.  PC state that 57 cents is both their 12-month and 24-month target price for AGH, which seems a bit odd.  Hope they haven't been trying the product...  AGH closed at 42 cents today (13-May-2020).